Physician profile
Diego Gomez
NPI 1003815408
$10,888.42
in general payments reported to CMS, 2019-2025
38 companies · $3,183 in 2025
The $3,183 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $822 · 2021: $732 · 2022: $896 · 2023: $1,658 · 2024: $2,026 · 2025: $3,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,823 · Education: $44.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.75 |
| Education | $44.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,481.05 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $857.00 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $790.05 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $717.63 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $630.03 | 2019-2025 | |
| Genzyme Corporation | $517.70 | 2023-2025 | |
| Pfizer INC. | $448.86 | 2019-2025 | |
| Celgene Corporation | $382.70 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $308.04 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $299.90 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $231.78 | 2019-2024 | Linzess |
| Qol Medical, LLC | $192.70 | 2023-2025 | Sucraid, Sucraid |
| Enterra Medical, INC. | $186.90 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $180.49 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $160.34 | 2025 | Rezdiffra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.